Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 14INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 7Other solid neoplasm 5Genitourinary 4Gastrointestinal 4Breast 3Tumor-Agnostic 1Thoracic 1

Conditions

Triple Negative Breast Neoplasms 2Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation 1Ovarian Neoplasms 1

Interventions

Trastuzumab 242Paclitaxel 223Fulvestrant 196Capecitabine 182Docetaxel 164Letrozole 142pembrolizumab 115Carboplatin 100exemestane 98Gemcitabine 98Cyclophosphamide 92palbociclib 86Anastrozole 83pertuzumab 78Lapatinib 73Bevacizumab 71ribociclib 68130-nm albumin-bound paclitaxel 66abemaciclib 59eribulin 58Doxorubicin 55Vinorelbine 51Injections 47Ado-Trastuzumab Emtansine 47Tamoxifen 45Everolimus 44Albumin-Bound Paclitaxel 44atezolizumab 35trastuzumab deruxtecan 34Nivolumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × fluzoparib × Breast × Clear all
NCT03945604 2022-08-12

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
32 enrolled
Breast

Triple Negative Breast Neoplasms

NCT03075462 2022-07-01

A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
98 enrolled
BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT04296370 2020-08-10

A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Unknown
474 enrolled
Breast

Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡